PLRZ: Pangali Forward P/E Polyrizon Ltd

Logo grafis polyrizon-biotech.com (PLRZ)

The projected P/E ratio for Polyrizon Ltd (PLRZ) on the GURU.Markets chart indicates the launch of protective sprays by 2026, with the 0.00 level serving as a critical benchmark. The startup is minimizing financial risks through the diversification of its respiratory drug portfolio. Additionally, Polyrizon Ltd is collaborating with laboratories to develop innovative nasal drug delivery systems designed to block viruses.

Polyrizon Ltd - Rasio rega marang bathi sing dikarepake PLRZ (periode 30.10.2024 - 10.11.2026)

Polyrizon Ltd. (PLRZ) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Bagan rega Polyrizon Ltd|PLRZ - Bagan rega target
- informasi kapitalisasi pasar:
Kapitalisasi pasar Polyrizon Limited|PLRZ - Rega Tumbas Perusahaan
- informasi kapitalisasi buku:
Nilai Akuntansi saben Saham Polyrizon|PLRZ - Nilai Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku polyrizon-biotech.com|PLRZ - Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Polyrizon Ltd|PLRZ - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Polyrizon Ltd|PLRZ - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Polyrizon Limited|PLRZ - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Polyrizon|Rasio cepet polyrizon-biotech.com
- rincian asil keuangan lan kelipatan valuasi:
PLRZ - Bathi resik|Bathi sing dikarepake Polyrizon Ltd|PLRZ - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Polyrizon Ltd|PLRZ - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Polyrizon Limited|PLRZ - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Polyrizon|PLRZ - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan polyrizon-biotech.com|PLRZ - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Polyrizon Ltd
Pambiji fundamental:PLRZ Polyrizon
Produk merek polyrizon-biotech.com

The forward P/E determines the market value of Polyrizon Ltd (PLRZ) relative to expected net income, allowing for an assessment of the premium paid for future earnings. By analyzing changes in the company's forward P/E, investors align market expectations with the efficiency of the business model, where the absence of proprietary plants and the utilization of global cGMP facilities reduce capital expenditures, directly impacting projected profitability and the final multiple.

Analisis pesaing Polyrizon Ltd

Rega marang bathi mangsa ngarep Vertex (VRTX)|Rega marang bathi mangsa ngarep ALNY (Alnylam Pharmaceuticals, Inc.)|Pangali Forward P/E INSM (Insmed Inc)|Kapitalisasi marang proyeksi bathi United Therapeutics Inc. (UTHR)|BMRN: Prakiraan rega marang bathi|Rasio rega marang bathi sing dikarepake BBIO|BGM: Pangali Forward P/E|Rasio prakiraan rega marang bathi Cogent Biosciences Inc (COGT)|XERS (Xeris Biopharma Inc) - Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep KROS (Keros Corp)|Prakiraan rega marang bathi ARCT (Arcturus Therapeutics)|ETON (etonpharma.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Kamada KMDA|FULC (Fulcrum Therapeutics Inc) - Rasio rega marang bathi sing dikarepake|Abeona - Pangali Forward P/E|Pangali mangsa ngarep rega marang bathi MREO (Mereo BioPharma)|PLX: Pangali Forward P/E|Pliant Therapeutics, Inc. (PLRX) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Applied Therapeutics, Inc.|RNTX: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Gelteq Limited (GELS)|Prakiraan rega marang bathi aytubio.com AYTU|Pangali Forward P/E CMMB (Chemomab Therapeutics Ltd.)|Pangali Forward P/E SRx Health Solutions Inc SRXH|AEZS - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake CYTH|inozyme.com (INZY) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Reneo Pharmaceuticals, Inc (RPHM)|Rega marang bathi mangsa ngarep COSCIENS Biopharma Inc.